{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T21:07:27Z","timestamp":1774645647793,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","oooojournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.oooo.2015.07.032","type":"journal-article","created":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T06:33:40Z","timestamp":1438410820000},"page":"594-601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Biological therapy and dentistry: a review paper"],"prefix":"10.1016","volume":"120","author":[{"given":"Lida","family":"Radfar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roshanak E.","family":"Ahmadabadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farah","family":"Masood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Hal","family":"Scofield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oooo.2015.07.032_bib1","first-page":"35","article-title":"The variety of types of adverse side-effects during treatment with biological drugs","volume":"18","author":"Mazurek","year":"2012","journal-title":"Int Rev Allergol Clin Immunol Fam Med"},{"issue":"suppl","key":"10.1016\/j.oooo.2015.07.032_bib2","first-page":"S124","article-title":"Defining and characterizing the late-state biopharmaceutical pipeline","volume":"9","author":"Nagle","year":"2003","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.oooo.2015.07.032_bib3","unstructured":"National Cancer Institute. Biological therapy for cancer fact sheet. Available at: http:\/\/www.cancer.gov\/cancertopics\/factsheet\/Therapy\/biological. Accessed June\u00a02013."},{"key":"10.1016\/j.oooo.2015.07.032_bib4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000289205","article-title":"The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions","volume":"11","author":"Sfikakis","year":"2010","journal-title":"Curr Dir Autoimmun"},{"key":"10.1016\/j.oooo.2015.07.032_bib5","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nbt1137","article-title":"Monoclonal antibody therapy of cancer","volume":"23","author":"Adams","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.oooo.2015.07.032_bib6","unstructured":"Cell signaling. In: Essentials of Cell Biology, Unit 4.1, and Cell Biology for Seminars, Unit 4.1. Available at: www.nature.com\/scitable\/topicpage\/cell-signaling-14047077."},{"key":"10.1016\/j.oooo.2015.07.032_bib7","unstructured":"Treatment and side effects of immunotherapy. Available at: http:\/\/www.cancer.org\/treatment\/treatmentsandsideeffects\/treatmenttypes\/immunotherapy\/immunotherapy-toc. (updated 2014)."},{"key":"10.1016\/j.oooo.2015.07.032_bib8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"issue":"suppl 3","key":"10.1016\/j.oooo.2015.07.032_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2133.2012.11208.x","article-title":"Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data","volume":"167","author":"Rustin","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.oooo.2015.07.032_bib10","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/intimm\/13.12.1551","article-title":"Differences in promiscuity for antibody\u2013FcRn interactions across species: implications for therapeutic antibodies","volume":"13","author":"Ober","year":"2001","journal-title":"Int Immunol"},{"key":"10.1016\/j.oooo.2015.07.032_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.critrevonc.2004.10.011","article-title":"Overview of monoclonal antibodies in cancer therapy: present and promise","volume":"54","author":"Stern","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.oooo.2015.07.032_bib12","unstructured":"Http\/\/www.d.umn.edu\/\u223cjfitzake\/Lectures\/MedSchool\/CytokineAntibodies\/Antibodies\/Nomenclature.htm."},{"key":"10.1016\/j.oooo.2015.07.032_bib13","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jaci.2005.03.028","article-title":"Adverse reactions to biologic agents: focus on autoimmune disease therapies","volume":"116","author":"Lee","year":"2005","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.oooo.2015.07.032_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1078-0432.CCR-09-2345","article-title":"Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies","volume":"16","author":"Campoli","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.oooo.2015.07.032_bib15","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1176\/appi.psy.45.4.354","article-title":"Immunosuppressants","volume":"45","author":"Fireman","year":"2004","journal-title":"Psychosomatics"},{"key":"10.1016\/j.oooo.2015.07.032_bib16","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3390\/antib2030426","article-title":"Molecular engineering of therapeutic cytokines","volume":"2","author":"Vazquez-Lombardi","year":"2013","journal-title":"Antibodies"},{"issue":"suppl 3","key":"10.1016\/j.oooo.2015.07.032_bib17","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1086\/430000","article-title":"Tumor necrosis factor inhibition and invasive fungal infections","volume":"41","author":"Filler","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.oooo.2015.07.032_bib18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11882-003-0072-z","article-title":"Secondary immune deficiencies associated with biological therapeutics","volume":"3","author":"Lee","year":"2003","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.oooo.2015.07.032_bib19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00000658-199002000-00002","article-title":"Tumor necrosis factor and wound healing","volume":"211","author":"Mooney","year":"1990","journal-title":"Ann Surg"},{"key":"10.1016\/j.oooo.2015.07.032_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/BF01922419","article-title":"Tumor necrosis factor-alpha inhibits collagen synthesis in human and rat granulation tissue fibroblasts","volume":"52","author":"Rapala","year":"1996","journal-title":"Experientia"},{"key":"10.1016\/j.oooo.2015.07.032_bib21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00000658-199108000-00012","article-title":"The local effects of cachectin\/tumor necrosis factor on wound healing","volume":"214","author":"Salomon","year":"1991","journal-title":"Ann Surg"},{"key":"10.1016\/j.oooo.2015.07.032_bib22","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/art.20312","article-title":"Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer","volume":"50","author":"Symmons","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.oooo.2015.07.032_bib23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/107110070402500510","article-title":"Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy","volume":"25","author":"Bibbo","year":"2004","journal-title":"Foot Ankle Int"},{"key":"10.1016\/j.oooo.2015.07.032_bib24","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3109\/08923973.2011.653646","article-title":"Safety of anti-TNF\u03b1 agents in the treatment of psoriasis and psoriatic arthritis","volume":"34","author":"Girolomoni","year":"2012","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.oooo.2015.07.032_bib25","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1741-7015-11-88","article-title":"Biologic therapy\u00a0for autoimmune diseases: an update","volume":"11","author":"Rosman","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.oooo.2015.07.032_bib26","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1365-2036.2004.01904.x","article-title":"The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study","volume":"19","author":"Marchal","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.oooo.2015.07.032_bib27","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1572-0241.2004.04148.x","article-title":"Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy","volume":"99","author":"Colombel","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.oooo.2015.07.032_bib28","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00054725-200409000-00025","article-title":"Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease","volume":"10","author":"Velayos","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.oooo.2015.07.032_bib29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/157339711794474620","article-title":"Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective","volume":"7","author":"De Keyser","year":"2011","journal-title":"Curr Rheum Rev"},{"key":"10.1016\/j.oooo.2015.07.032_bib30","doi-asserted-by":"crossref","first-page":"W","DOI":"10.7326\/0003-4819-139-3-200308050-00021-w4","article-title":"Severe neutropenia and thrombocytopenia associated with infliximab","volume":"139","author":"Vidal","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.oooo.2015.07.032_bib31","first-page":"817","article-title":"Leukopenia and thrombocytopenia induced by etanercept: two case reports and literature review","volume":"52","author":"Azevedo","year":"2012","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.oooo.2015.07.032_bib32","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1136\/ard.2006.056176","article-title":"Neutropenia while receiving. anti-tumour necrosis factor treatment for rheumatoid arthritis","volume":"65","author":"Rajakulendran","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.oooo.2015.07.032_bib33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0889-857X(05)70211-8","article-title":"Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. Review","volume":"27","author":"Keystone","year":"2001","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.oooo.2015.07.032_bib34","first-page":"689","article-title":"Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study","volume":"34","author":"den Broeder","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.oooo.2015.07.032_bib35","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00403-006-0694-9","article-title":"The incidence of\u00a0arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: Pooled analysis of data from phase III clinical trials of efalizumab","volume":"298","author":"Pincelli","year":"2006","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.oooo.2015.07.032_bib36","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.autrev.2011.04.010","article-title":"Anti-TNF therapy: safety aspects of taking the risk","volume":"10","author":"Rosenblum","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.oooo.2015.07.032_bib37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.oooo.2015.07.032_bib38","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oooo.2015.07.032_bib39","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.oooo.2015.07.032_bib40","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3109\/s10165-006-0530-2","article-title":"Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis","volume":"17","author":"Yamamoto","year":"2007","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.oooo.2015.07.032_bib41","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s11910-013-0408-6","article-title":"Progressive multifocal leukoencephalopathy in multiple sclerosis","volume":"13","author":"Chalkley","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.oooo.2015.07.032_bib42","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1902\/jop.2014.140194","article-title":"Periodontal and serum protein profiles in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitor adalimumab","volume":"85","author":"Kobayashi","year":"2014","journal-title":"J\u00a0Periodontol"},{"key":"10.1016\/j.oooo.2015.07.032_bib43","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1902\/jop.2009.080447","article-title":"Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors","volume":"80","author":"Ortiz","year":"2009","journal-title":"J\u00a0Periodontol"},{"key":"10.1016\/j.oooo.2015.07.032_bib44","first-page":"180","article-title":"Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis","volume":"18","author":"Savioli","year":"2012","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.oooo.2015.07.032_bib45","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s11926-014-0408-9","article-title":"The link between periodontal disease and rheumatoid arthritis an updated review","volume":"16","author":"Koziel","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.oooo.2015.07.032_bib46","unstructured":"Xynos ID, Sipsas NV. Infectious complications of anti-tumour necrosis factor-\u03b1 therapy in rheumatoid arthritis. Available at: http:\/\/www.intechopen.com\/books\/insights-and-perspectives-inrheumatology\/infectious-complications-of-anti-tumour-necrosis-factor-therapy-in-rheumatoid-arthritis."},{"issue":"suppl 2","key":"10.1016\/j.oooo.2015.07.032_bib47","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1136\/annrheumdis-2013-203348","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012","volume":"72","author":"Furst","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.oooo.2015.07.032_bib48","series-title":"Dental management of medically compromised patient","author":"Little","year":"2008"},{"key":"10.1016\/j.oooo.2015.07.032_bib49","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","article-title":"British Association of Dermatologists\u2019 guidelines for biologic interventions for psoriasis 2009","volume":"161","author":"Smith","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.oooo.2015.07.032_bib50","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/01.CIR.0000093201.57771.47","article-title":"Nonvalvular cardiovascular device-related infections","volume":"108","author":"Baddour","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.oooo.2015.07.032_bib51","doi-asserted-by":"crossref","first-page":"222","DOI":"10.14712\/fb2007053060222","article-title":"The spectrum and types of adverse side effects to biological immune modulators: a proposal for new classification [retracted]","volume":"53","author":"Zemkova","year":"2007","journal-title":"Folia Biol"},{"key":"10.1016\/j.oooo.2015.07.032_bib52","unstructured":"http:\/\/www.kineretrx.com\/healthcare-practitioner\/."},{"key":"10.1016\/j.oooo.2015.07.032_bib53","unstructured":"http:\/\/www.xeljanzhcp.com\/Comparison biological agents\/drugs and traditional drugs."},{"key":"10.1016\/j.oooo.2015.07.032_bib54","unstructured":"https:\/\/www.humira.com\/."},{"key":"10.1016\/j.oooo.2015.07.032_bib55","unstructured":"http:\/\/www.actemrahcp.com\/."},{"key":"10.1016\/j.oooo.2015.07.032_bib56","unstructured":"http:\/\/www.gene.com\/download\/pdf\/xolair_prescribing.pdf."},{"key":"10.1016\/j.oooo.2015.07.032_bib57","unstructured":"http:\/\/www.adcetris.com\/hcp\/."},{"key":"10.1016\/j.oooo.2015.07.032_bib58","unstructured":"http:\/\/www.rxlist.com\/zenapax-drug\/side-effects-interactions.htm."},{"key":"10.1016\/j.oooo.2015.07.032_bib59","unstructured":"http:\/\/www.zevalin.com\/downloads\/Zevalin_Package_Insert.pdf."},{"key":"10.1016\/j.oooo.2015.07.032_bib60","unstructured":"http:\/\/www.rxlist.com\/simulect-drug.htm."},{"key":"10.1016\/j.oooo.2015.07.032_bib61","unstructured":"http:\/\/www.rxlist.com\/reopro-drug\/indications-dosage.htm."},{"key":"10.1016\/j.oooo.2015.07.032_bib62","unstructured":"http:\/\/www.drugs.com\/pro\/orthoclone-okt3.html."},{"key":"10.1016\/j.oooo.2015.07.032_bib63","unstructured":"http:\/\/www.tysabrihcp.com."},{"key":"10.1016\/j.oooo.2015.07.032_bib64","unstructured":"http:\/\/www.orencia.com\/hcp\/index.aspx?requestUrl=http:\/\/orencia-sp-pub.bms.com\/hcp\/healthcare-professionals.aspx."},{"key":"10.1016\/j.oooo.2015.07.032_bib65","unstructured":"http:\/\/www.enbrel.com."}],"container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221244031501130X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221244031501130X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T21:00:47Z","timestamp":1748552447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221244031501130X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S221244031501130X"],"URL":"https:\/\/doi.org\/10.1016\/j.oooo.2015.07.032","relation":{},"ISSN":["2212-4403"],"issn-type":[{"value":"2212-4403","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biological therapy and dentistry: a review paper","name":"articletitle","label":"Article Title"},{"value":"Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oooo.2015.07.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}